Xavier Pivot1, Mark Pegram2, Javier Cortes3, Diana Lüftner4, Gary H Lyman5, Giuseppe Curigliano6, Igor Bondarenko7, Ye Chan Yoon8, Younsoo Kim8, Chul Kim8. 1. Paul Strauss Center, Strasbourg, France. Electronic address: xpivot@strasbourg.unicancer.fr. 2. Stanford Comprehensive Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA. 3. Vall D'Hebron Institute of Oncology (VHIO), Barcelona and Ramon y Cajal University Hospital, Madrid, Spain. 4. Charité Campus Benjamin Franklin, Humboldt University, Berlin, Germany. 5. Fred Hutchinson Cancer Research Center, Seattle, WA, USA. 6. IEO, European Institute of Oncology IRCCS, Milano, Italy; University of Milano, Milano, Italy. 7. Dnipropetrovsk Medical Academy, Dnipro, Ukraine. 8. Samsung Bioepis Co., Ltd., Incheon, Republic of Korea.
Abstract
BACKGROUND: We assessed long-term cardiac safety and efficacy in patients with human epidermal growth factor receptor 2-positive early breast cancer treated with atrastuzumab biosimilar (SB3) or its reference product, trastuzumab (TRZ), in a phase 3 study. METHODS:Patients who completed the phase 3 study could be enrolled in this extension study. The outcomes included the incidence of symptomatic congestive heart failure (CHF), asymptomatic significant left ventricular ejection fraction (LVEF) decrease, incidence of other cardiac events, event-free survival (EFS), and overall survival. In post hoc analysis, the Cox proportional hazards regression model was used to assess factors associated with EFS. RESULTS: A total of 367 patients were enrolled in the study (SB3, n = 186; TRZ, n = 181). The median follow-up duration from the main study enrolment was 40.8 and 40.5 months for SB3 and TRZ, respectively. During the two-year follow-up after adjuvant therapy, incidence of asymptomatic significant LVEF decrease was rare (SB3, n = 1; TRZ, n = 2), with all patients recovering with LVEF ≥ 50%, and no cases of symptomatic CHF or other cardiac events were reported. At 3 years, the EFS was 91.9% with SB3 and 85.2% with TRZ. The number of patients with events was 17 (9.1%) with SB3 and 31 (17.1%) with TRZ [hazard ratio: 0.47, 95% confidence interval: 0.26-0.87]. Antibody-dependent cell-mediated cytotoxicity (ADCC) activity and the breast pathologic complete response rate were the factors associated with EFS. CONCLUSION:Cardiotoxicity was rare in this extension study. EFS was higher with SB3 versus TRZ, with post hoc analysis suggesting that a downward drift in ADCC activity was a contributing factor. CLINICAL TRIAL REGISTRATION NUMBERS: NCT02771795 (EudraCT 2015-005663-17).
RCT Entities:
BACKGROUND: We assessed long-term cardiac safety and efficacy in patients with humanepidermal growth factor receptor 2-positive early breast cancer treated with a trastuzumab biosimilar (SB3) or its reference product, trastuzumab (TRZ), in a phase 3 study. METHODS:Patients who completed the phase 3 study could be enrolled in this extension study. The outcomes included the incidence of symptomatic congestive heart failure (CHF), asymptomatic significant left ventricular ejection fraction (LVEF) decrease, incidence of other cardiac events, event-free survival (EFS), and overall survival. In post hoc analysis, the Cox proportional hazards regression model was used to assess factors associated with EFS. RESULTS: A total of 367 patients were enrolled in the study (SB3, n = 186; TRZ, n = 181). The median follow-up duration from the main study enrolment was 40.8 and 40.5 months for SB3 and TRZ, respectively. During the two-year follow-up after adjuvant therapy, incidence of asymptomatic significant LVEF decrease was rare (SB3, n = 1; TRZ, n = 2), with all patients recovering with LVEF ≥ 50%, and no cases of symptomatic CHF or other cardiac events were reported. At 3 years, the EFS was 91.9% with SB3 and 85.2% with TRZ. The number of patients with events was 17 (9.1%) with SB3 and 31 (17.1%) with TRZ [hazard ratio: 0.47, 95% confidence interval: 0.26-0.87]. Antibody-dependent cell-mediated cytotoxicity (ADCC) activity and the breast pathologic complete response rate were the factors associated with EFS. CONCLUSION:Cardiotoxicity was rare in this extension study. EFS was higher with SB3 versus TRZ, with post hoc analysis suggesting that a downward drift in ADCC activity was a contributing factor. CLINICAL TRIAL REGISTRATION NUMBERS: NCT02771795 (EudraCT 2015-005663-17).
Authors: Justin Stebbing; Paul N Mainwaring; Giuseppe Curigliano; Mark Pegram; Mark Latymer; Angel H Bair; Hope S Rugo Journal: J Clin Oncol Date: 2020-02-14 Impact factor: 44.544
Authors: Andreas D Hartkopf; Volkmar Müller; Achim Wöckel; Michael P Lux; Wolfgang Janni; Johannes Ettl; Erik Belleville; Florian Schütz; Peter A Fasching; Hans-Christian Kolberg; Manfred Welslau; Friedrich Overkamp; Florin-Andrei Taran; Sara Y Brucker; Markus Wallwiener; Hans Tesch; Tanja N Fehm; Andreas Schneeweiss; Diana Lüftner Journal: Geburtshilfe Frauenheilkd Date: 2019-12-11 Impact factor: 2.915
Authors: Antonino Musolino; William J Gradishar; Hope S Rugo; Jeffrey L Nordstrom; Edwin P Rock; Fernanda Arnaldez; Mark D Pegram Journal: J Immunother Cancer Date: 2022-01 Impact factor: 13.751
Authors: Denis M Collins; Stephen F Madden; Nicola Gaynor; Dalal AlSultan; Marion Le Gal; Alex J Eustace; Kathy A Gately; Clare Hughes; Anthony M Davies; Thamir Mahgoub; Jo Ballot; Sinead Toomey; Darran P O'Connor; William M Gallagher; Frankie A Holmes; Virginia Espina; Lance Liotta; Bryan T Hennessy; Kenneth J O'Byrne; Max Hasmann; Birgit Bossenmaier; Norma O'Donovan; John Crown Journal: Clin Cancer Res Date: 2020-10-29 Impact factor: 13.801
Authors: Hope S Rugo; Eduardo J Pennella; Unmesh Gopalakrishnan; Miguel Hernandez-Bronchud; Jay Herson; Hans Friedrich Koch; Subramanian Loganathan; Sarika Deodhar; Ashwani Marwah; Alexey Manikhas; Igor Bondarenko; Guzel Mukhametshina; Gia Nemsadze; Joseph D Parra; Maria Luisa T Abesamis-Tiambeng; Kakhaber Baramidze; Charuwan Akewanlop; Ihor Vynnychenko; Virote Sriuranpong; Gopichand Mamillapalli; Sirshendu Roy; Eduardo Patricio Yanez Ruiz; Abhijit Barve; Adolfo Fuentes-Alburo; Cornelius F Waller Journal: Breast Cancer Res Treat Date: 2021-06-14 Impact factor: 4.872